Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635746 | 0.90 | NPC1 (0.46) | NPC1RAB9APOLBMAPTALDH1A1 | |
| SCHEMBL2635722 | 0.83 | LMNA (0.38) | RAB9ASMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL2635943 | 0.83 | TDP1 (0.49) | SMN1; SMN2POLBMAPTALDH1A1KMT2A | |
| SCHEMBL2636074 | 0.81 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2635914 | 0.79 | ALDH1A1 (0.42) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2635847 | 0.79 | GAA (0.42) | POLBMAPTALDH1A1LMNAGAA | |
| SCHEMBL2635555 | 0.78 | MAPT (0.52) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL2635997 | 0.78 | ACLY (0.44) | SMN1; SMN2POLBMAPTALDH1A1LMNA | |
| SCHEMBL2636251 | 0.77 | RAB9A (0.56) | RAB9ASMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL2636019 | 0.77 | MAPT (0.50) | NPC1RAB9ASMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | NPC1 215/4885RAB9A 2053/4885SMN1; SMN2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.